Literature DB >> 35830003

Traditional use of benznidazole with weekly clinical follow-up indicate to be an important approach for the etiologic treatment of Chagas disease.

Gilberto Marcelo Sperandio da Silva1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35830003      PMCID： PMC9273180          DOI： 10.1590/0074-02760210034chgsa

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN： 0074-0276            Impact factor:   2.747


× No keyword cloud information.
  4 in total

1.  2 nd Brazilian Consensus on Chagas Disease, 2015.

Authors:  João Carlos Pinto Dias; Alberto Novaes Ramos; Eliane Dias Gontijo; Alejandro Luquetti; Maria Aparecida Shikanai-Yasuda; José Rodrigues Coura; Rosália Morais Torres; José Renan da Cunha Melo; Eros Antonio de Almeida; Wilson de Oliveira; Antônio Carlos Silveira; Joffre Marcondes de Rezende; Fabiane Scalabrini Pinto; Antonio Walter Ferreira; Anis Rassi; Abílio Augusto Fragata; Andréa Silvestre de Sousa; Dalmo Correia; Ana Maria Jansen; Glaucia Manzan Queiroz Andrade; Constança Felícia De Paoli de Carvalho Britto; Ana Yecê das Neves Pinto; Anis Rassi; Dayse Elisabeth Campos; Fernando Abad-Franch; Silvana Eloi Santos; Egler Chiari; Alejandro Marcel Hasslocher-Moreno; Eliane Furtado Moreira; Divina Seila de Oliveira Marques; Eliane Lages Silva; José Antonio Marin-Neto; Lúcia Maria da Cunha Galvão; Sergio Salles Xavier; Sebastião Aldo da Silva Valente; Noêmia Barbosa Carvalho; Alessandra Viana Cardoso; Rafaella Albuquerque E Silva; Veruska Maia da Costa; Simone Monzani Vivaldini; Suelene Mamede Oliveira; Vera da Costa Valente; Mayara Maia Lima; Renato Vieira Alves
Journal:  Rev Soc Bras Med Trop       Date:  2016-12       Impact factor: 1.581

2.  Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas' disease.

Authors:  Gilberto Marcelo Sperandio da Silva; M F F Mediano; Alejandro Marcel Hasslocher-Moreno; Marcelo Teixeira de Holanda; Andrea Silvestre de Sousa; Luiz Henrique Conde Sangenis; Pedro Emmanuel Alvarenga Americano do Brasil; Roger Arteaga Mejía; Carina Perotti Fux; Juan-Carlos Cubides; Roberto Magalhães Saraiva; Lucia Maria Brum-Soares
Journal:  J Antimicrob Chemother       Date:  2017-09-01       Impact factor: 5.790

3.  New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial.

Authors:  Faustino Torrico; Joaquim Gascón; Fabiana Barreira; Bethania Blum; Igor C Almeida; Cristina Alonso-Vega; Tayná Barboza; Graeme Bilbe; Erika Correia; Wilson Garcia; Lourdes Ortiz; Rudy Parrado; Juan Carlos Ramirez; Isabela Ribeiro; Nathalie Strub-Wourgaft; Michel Vaillant; Sergio Sosa-Estani
Journal:  Lancet Infect Dis       Date:  2021-04-06       Impact factor: 71.421

4.  Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study.

Authors:  Alejandro M Hasslocher-Moreno; Roberto M Saraiva; Luiz H C Sangenis; Sergio S Xavier; Andrea S de Sousa; Andrea R Costa; Marcelo T de Holanda; Henrique H Veloso; Fernanda S N S Mendes; Filipe A C Costa; Marcio N Boia; Pedro E A A Brasil; Fernanda M Carneiro; Gilberto M Sperandio da Silva; Mauro F F Mediano
Journal:  EClinicalMedicine       Date:  2020-12-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.